European Archives of Psychiatry and Clinical Neuroscience
December 2011
Laura Kranaster, Jutta Kammerer-Ciernioch, Carolin Hoyer et al.
In a retrospective chart review, we examined the effects of ketamine, an N-methyl-d-aspartate (NMDA) receptor antagonist, as electroconvulsive therapy (ECT) anaesthetic in patients suffering from therapy-resistant depression. We included 42 patients who received ECT treatment with either ketamine (n = 16) or the barbiturate thiopental (n = 26). We analysed the number of sessions until...
Neuropsychopharmacology
December 2011
Samantha L Rushforth, Thomas Steckler, Mohammed Shoaib
Ketamine, an NMDA-receptor antagonist, produces cognitive deficits in humans in a battery of tasks involving attention and memory. Nicotine can enhance various indices of cognitive performance, including working memory span capacity measured using the odor span task (OST). This study examined the effects of a sub-chronic ketamine treatment to model cognitive deficits associated with...
The International Journal of Neuropsychopharmacology
November 24, 2011
Jason M. Dwyer, Ashley E. Lepack, Ronald S. Duman
169 citations
Recent studies demonstrate that ketamine, a fast-acting antidepressant, rapidly activates the mammalian target of rapamycin (mTOR) and increases synaptogenesis in the prefrontal cortex. Because of the side-effect and abuse potential of ketamine we are investigating alternative agents that produce similar effects. Here, we demonstrate that a single dose of LY 341495, an mGluR₂/₃ antagonist,...
The International Journal of Neuropsychopharmacology
November 1, 2011
Giacomo Salvadore, Jan Willem van der Veen, Yan Zhang et al.
105 citations
Amino-acid neurotransmitter system dysfunction plays a major role in the pathophysiology of major depressive disorder (MDD). We used proton magnetic resonance spectroscopy (¹H-MRS) to investigate whether prefrontal levels of amino-acid neurotransmitters predict antidepressant response to a single intravenous infusion of the N-methyl-D-aspartate (NMDA) antagonist ketamine in MDD patients....
Anesthesiology
October 1, 2011
Jing Wang, Yossef Goffer, Duo Xu et al.
171 citations
BACKGROUND: Chronic pain is associated with depression. In rodents, pain is often assessed by sensory hypersensitivity, which does not sufficiently measure affective responses. Low-dose ketamine has been used to treat both pain and depression, but it is not clear whether ketamine can relieve depression associated with chronic pain and whether this antidepressant effect depends on its...
Psychopharmacology
September 15, 2011
Agnieszka Nikiforuk, Piotr Popik
Rationale: Prefrontal cortical dysfunctions, including an impaired ability to shift perceptual attentional set, are core features of schizophrenia. Nevertheless, the effectiveness of second-generation antipsychotic drugs in treating specific prefrontal dysfunctions remains equivocal. Objectives: To model schizophrenia-like cognitive inflexibility in rats, we evaluated the effects of repeated...
Pharmacopsychiatry
September 1, 2011
Patrik Roser, IS Haussleiter, HJ Chong et al.
2 citations
Preclinical and clinical research suggests that the endogenous cannabinoid system is involved in cognitive impairments related to schizophrenia. In particular, deficient generation of mismatch negativity (MMN) indicating auditory sensory memory is a characteristic finding in schizophrenic patients. Experimental studies implicate deficient N-methyl-D-aspartate (NMDA) receptor functioning in such...
International Clinical Psychopharmacology
September 1, 2011
Silvia Sorce, Stefania Schiavone, Paolo Tucci et al.
The 15th Biennial Winter Workshop in Psychoses, 15–18 November 2009, Barcelona, Spain: DRUG INDUCED PSYCHOSES
International Clinical Psychopharmacology
September 1, 2011
Hannah L. Morgan, J.C. Coull, J.G. Moore et al.
The 16th Biennial Winter Workshop in Psychoses, 30 January to 2 February 2011 Innsbruck, Austria: POSTER ABSTRACTS
Pharmacopsychiatry
September 1, 2011
Milan Scheidegger, Anke Henning, Martin Walter et al.
Background: Ketamine is a potent NMDA receptor antagonist with rapid antidepressant properties at subanaesthetic doses. This multimodal imaging study reveals the effects of a subanaesthetic ketamine infusion on fMRI-BOLD responses during an emotional processing task and their relationship to glutamatergic metabolite concentrations in the pregenual anterior cingulate cortex (PACC) assessed by...
Pharmacopsychiatry
September 1, 2011
Simone Grimm, Milan Scheidegger, Anke Henning et al.
Ketamine is a potent glutamatergic NMDA receptor antagonist with rapid antidepressant properties, thus providing a valuable research tool for the investigation of the neurobiology of major depressive disorder (MDD). Increasing evidence underscores the role of glutamate dependent neuroplasticity and glutamatergic neurotransmission and metabolism in the pathophysiology of MDD. This multimodal...
Journal of Neuroscience
August 10, 2011
Samuel A Neymotin, Maciej T Lazarewicz, Mohamed Sherif et al.
Abnormalities in oscillations have been suggested to play a role in schizophrenia. We studied theta-modulated gamma oscillations in a computer model of hippocampal CA3 in vivo with and without simulated application of ketamine, an NMDA receptor antagonist and psychotomimetic. Networks of 1200 multicompartment neurons [pyramidal, basket, and oriens-lacunosum moleculare (OLM) cells] generated...
Journal of Anesthesia
August 2011
Joon-Ho Lee, Sung-Hwan Cho, Sang-Hyun Kim et al.
We investigated the heat pain threshold (HPT) and temporal summation threshold (TST) before and after target-controlled infusion (TCI) of ketamine with an effect-site concentration (Ce) of 30 and 60 ng/ml. Healthy young volunteers (n = 20) were enrolled. A thermode was applied to the volar side of each volunteer's right forearm, and HPT and TST were measured before and after TCI of ketamine....
Psychological Medicine
August 1, 2011
Letter to the editor: does ketamine exert a fast-acting antidepressant effect via inhibition of pro-inflammatory cytokines?
Clinical Pharmacology & Therapeutics
August 2011
Marko A. Peltoniemi, Teijo I. Saari, Nora M. Hagelberg et al.
This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at...
Addiction
July 21, 2011
Celia J. A. Morgan, Helen Valerie Curran
645 citations
AIMS: Ketamine remains an important medicine in both specialist anaesthesia and aspects of pain management. At the same time, its use as a recreational drug has spread in many parts of the world during the past few years. There are now increasing concerns about the harmful physical and psychological consequences of repeated misuse of this drug. The aim of this review was to survey and integrate...
Biological Psychology
July 13, 2011
Verner J Knott, Anne M Millar, Judy F McIntosh et al.
Given the cognitive-promoting properties of the nicotinic acetylcholinergic receptor (nAChR) agonist, nicotine, the increased prevalence of smoke-inhaled nicotine in schizophrenia has been interpreted as an attempt to self-correct cognitive deficits, which have been particularly pronounced in the attentional domain. As glutamatergic abnormalities have been implicated in these attentional...
American Journal of Psychiatry
July 1, 2011
Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation.
Neuroimage
June 29, 2011
Ketamine effects on brain function--simultaneous fMRI/EEG during a visual oddball task.
PLoS One
June 21, 2011
Gene expression changes in GABA(A) receptors and cognition following chronic ketamine administration in mice.